Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: herry iball who wrote (56228)	7/25/2000 9:33:39 AM
From: chapin	Read Replies (1) \| Respond to of 150070

(BSNS WIRE) Catalyst -``CLYC''- to Become DNAPrint genomics, Inc. -''DNAP'' Catalyst -``CLYC''- to Become DNAPrint genomics, Inc. -''DNAP''- Business Editors/Health & Medical Writers SARASOTA, Fla.--(BUSINESS WIRE)--July 25, 2000--Catalyst Communications, Inc. (Pink Sheets:CLYC) announced today that it is changing its name to DNAPrint genomics, Inc., and its symbol to "DNAP". The name and symbol change will become effective on July 26th, 2000. All future communications and securities filings will be made under this new name and symbol. The Company has begun initial preparations to file its Form 10SB with the goal of becoming a reporting company under the provisions of the Securities Exchange Act of 1934, as amended, so it will be eligible to be quoted on the NASD's OTC Bulletin Board prior to year-end. The Company currently has no intentions of executing a reverse stock-split. About DNAPrint genomics DNAPrint genomics, Inc. will provide practitioners of genomic research and personalized medicine with a comprehensive system for disease dissection and patient classification. Physicians will be able to use the company's system, through a combination of on-site hardware/software placement and ASP (application-service provider) resources, to draw highly sophisticated conclusions and associations between patient genotype data and database patterns from historical studies. Many of these studies will be performed by DNAPrint genomics and/or it's partners. The analytical heart of the system is a collection of sophisticated algorithms that enable a progression from the multivariate dissection of high-density genotype matrices to multi-dimensional associations with complex human traits. The system uses a variety of novel mathematical modeling and programming techniques, which comprise the bulk of the companies budding intellectual property portfolio. The company has already filed patent applications for a genetic analysis reagent that confers considerable advantages for high-throughput DNA sequencing and genotyping, and has filed applications for five trade and/or service marks connected with the companies business model. The company intends to patent the application of its informatics platform to the field of genomic research and for personalized medical applications. During the development phase of this informatics platform, the company performs genetic variation studies on a number of different target areas, including drug response and cancer. Not only do these targets provide a comprehensive training set for the algorithms and models developed by the company, but the genetic patterns discovered through the analysis represent separate, and valuable assets. For example, the application of the informatics platform to patients which exhibit side-effects for a certain drug can produce a valuable diagnostic product which could reduce patient morbidity associated with the use of that drug. The company intends to patent and use these "information" assets to generate near-term revenue growth and profitability. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. For more information about the company, please visit www.dnaprint.com. Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties. The Company's actual results could differ materially from those contained in such statements. Factors that could cause or contribute to such differences include unexpected shortages of critical components, rescheduling or cancellation of customer orders, the timing and market acceptance of new product introductions by the Company and its competitors, and general competition and price pressures in the marketplace. --30--cp/mi* CONTACT: For scientific inquiries: DNAPrint genomics, Inc., Sarasota Dr. Tony Frudakis, 941/351-4543 or All other inquiries: Richard Craig Hall, 941/341-0136 KEYWORD: FLORIDA INDUSTRY KEYWORD: MEDICAL BIOTECHNOLOGY HARDWARE SOFTWARE Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com * end of story *